Darleukin, Fibromun
PH-L19IL2TNF-02/15
Phase 3 small_molecule active
Quick answer
Darleukin, Fibromun for Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions is a Phase 3 program (small_molecule) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Philogen S.p.A.
- Indication
- Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active